<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707418</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00176475</org_study_id>
    <nct_id>NCT03707418</nct_id>
  </id_info>
  <brief_title>Bivalirudin vs Heparin in ECMO Patients</brief_title>
  <official_title>A Randomized Study Comparing Bivalirudin vs Heparin in Patients With Extracorporeal Membrane Oxygenator (ECMO) Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomized study comparing the clinical outcomes of unfractionated
      Heparin and Bivalirudin for anticoagulation in adult subjects requiring ECMO support.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open label randomized study will compare the clinical outcomes of patients on ECMO who
      are anticoagulated with Heparin and Bivalirudin. Patients will be anticoagulated with a
      heparin bolus at the commencement of ECMO per standard of care, as there will be insufficient
      time to randomize these frequently emergent patients. Consent for the study will be obtained
      from a legally authorized representative Prior to starting a continuous infusion of
      maintenance anticoagulation, patients will be randomized to bivalirudin or heparin. Outcome
      measures are bleeding, thrombosis, development of Heparin Induced thrombocytopenia, number of
      cross-overs between the two research arms, circuit failures, decannulation, deaths and
      discharges from hospital.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of heparin-induced thrombocytopenia (HIT) events</measure>
    <time_frame>30 days</time_frame>
    <description>This will be assessed by serum platelet factor 4 antibody level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Cross-overs between arms</measure>
    <time_frame>30 days</time_frame>
    <description>This will be assessed by number of cross over of patients from one arm to the other anti-coagulation arm for any particular clinical reason.
Crossover patients will remain in the study and we will continue to collect protocol driven data. These patients will be analyzed separately from those with no cross-over.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of circuit failures requiring a circuit exchange</measure>
    <time_frame>30 days</time_frame>
    <description>Will be determined by total number of circuit exchanges needed in ECMO circuit due to thrombosis. Circuit exchanges may be done due to lack of adequate gas exchange or increased resistance pre and post oxygenator &gt;50mmHg, circuit thrombosis or failure requiring emergent decannulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombotic events</measure>
    <time_frame>30 days</time_frame>
    <description>Collect number of thrombotic events, defined as any of the following events; embolic strokes, embolic end-organ ischemia, embolic ischemia to limbs, deep vein thrombosis or venous thromboembolism, Oxygenator effectiveness measured by resistance, Alveolar-arterial oxygen gradient and carbon dioxide elimination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>30 days</time_frame>
    <description>Will be assessed by the total number of one or more of the following: Chest tube output of blood, number of take-backs to operating room for bleeding, number of Hemorrhagic strokes, Gastrointestinal bleeding, Retroperitoneal hemorrhage, number of cessations of anticoagulation for refractory bleeding and any use of antifibrinolytics or factor VII</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal failure</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as initiation of renal replacement therapy for kidney injury that develops on ECMO or increase in serum creatinine by more than 2 times its baseline or decrease in Glomerular Filtration Rate by more than 50% or urine output less than 0.3 mL/kg/hr. We will determine the number of patients with renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Transfusions</measure>
    <time_frame>30 days</time_frame>
    <description>This will be assessed by any of the following: number of utilizations of packed red blood cells and utilization of fresh frozen plasma, utilization of platelets, utilization of cryoprecipitate, utilization of anti-thrombin III, utilization of factor VII, utilization of prothrombin complex concentrate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of emergent decannulations</measure>
    <time_frame>30 days</time_frame>
    <description>This will be assessed by the number of times patient is separated from ECMO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients surviving to discharge</measure>
    <time_frame>30 days</time_frame>
    <description>This will be assessed by the number of patients in each arm who survive to discharge</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <arm_group>
    <arm_group_label>Bivalirudin Injection (Angiomax)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin Sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin Sodium</intervention_name>
    <description>Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels</description>
    <arm_group_label>Heparin Sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin Injection [Angiomax]</intervention_name>
    <description>Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels</description>
    <arm_group_label>Bivalirudin Injection (Angiomax)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients on veno-arterial (VA) or veno-venous (VV)ECMO

        Exclusion Criteria:

          -  Patient or surrogate decision makers cannot provide informed consent.

          -  Patients who have intolerance to either heparin or bivalirudin

          -  Patients who received any form of thrombolytic therapy within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Whitman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judi Willhide, RN</last_name>
    <phone>410-955-3597</phone>
    <email>jwillhi3@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Choi, M.D.</last_name>
    <phone>410-955-2800</phone>
    <email>cchoi40@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

